The objective of this paper is to analyse serum levels of anti-C1q, C1q circulating immune complexes (CIC), complement activation and complement components in systemic lupus erythematosus (SLE) patients during the first central nervous system neuropsychiatric (NP) event and to define the possible association between these results and clinical and laboratory characteristics.
Methods
A total of 280 patients suspected of having NP involvement due to SLE were recruited in the Leiden NPSLE-clinic. All SLE patients were classified according to the ACR 1982 revised criteria for the classification of SLE. The clinical disease activity was measured by the SLE Disease Activity Index 2000 (SLEDAI-2K) and NP diagnoses were classified according to the 1999 ACR case definitions for NPSLE. We measured in serum of all patients anti-C1q and C1q CIC levels, the activation capacity of complement (CH50 and AP50) and different complement components (C1q, C3, C4).
Results
In 92 patients the symptoms were attributed to SLE. NPSLE patients consisted of 63 patients with focal NPSLE and 34 patients with diffuse NPSLE. Anti-C1q antibodies were significantly higher and CH50, AP50 and C3 were significantly lower in NPSLE patients compared with SLE patients without NPSLE. This association was specially marked for diffuse NPSLE while no differences were found for focal NPSLE. After using potential predictors, decreased C4 remained significantly associated with focal NPSLE, but only when antiphospholipid antibodies (aPL) were included in the model. C3 and AP50 were independently associated with diffuse NPSLE. When SLEDAI-2K was included in the model these two associations were lost. When individual NPSLE syndromes were analysed, psychosis and cognitive dysfunction showed significantly lower values of complement activation capacity and all complement components. No significant associations were seen for other individual NPSLE syndromes.
Conclusion
The associations between diffuse NPSLE and anti-C1q, C3/AP50 and focal NPSLE and C4 may be explained by disease activity and the presence of aPL, respectively. The role of complement activation and complement components in lupus psychosis and cognitive dysfunction merits further research.
LefflerJBengtssonAABlomAM. The complement system in systemic lupus erythematosus: An update. Ann Rheum Dis2014; 73: 1601–1606.
2.
SturfeltGTruedssonL. Complement and its breakdown products in SLE. Rheumatology (Oxford)2005; 44: 1227–1232.
3.
MahlerMSchaarenburgRATrouwLA. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol2013; 4: 117–117.
4.
AlexanderJJQuiggRJ. Systemic lupus erythematosus and the brain: What mice are telling us. Neurochem Int2007; 50: 5–11.
5.
DiamondBHuertaPTMina-OsorioPKowalCVolpeBT. Losing your nerves? Maybe it’s the antibodies. Nat Rev Immunol2009; 9: 449–456.
6.
FärberKCheungGMitchellD. C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. J Neurosci Res2009; 87: 644–652.
7.
BertsiasGKBoumpasDT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol2010; 6: 358–367.
8.
VeerhuisRNielsenHMTennerAJ. Complement in the brain. Mol Immunol2011; 48: 1592–1603.
9.
JongenPJDoesburgWHIbrahim-StappersJLLemmensWAHommesORLamersKJ. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand2000; 101: 116–121.
10.
KarassaFBIoannidisJPTouloumiGBokiKAMoutsopoulosHM. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM2000; 93: 169–174.
11.
SandersMEAlexanderELKoskiCLFrankMMJoinerKA. Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren’s syndrome or systemic lupus erythematosus. J Immunol1987; 138: 2095–2099.
12.
PeerschkeEIYinWAlpertDRRoubeyRASalmonJEGhebrehiwetB. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus2009; 18: 530–538.
13.
LoodCTydénHGullstrandB. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One2014; 9: e99386–e99386.
14.
AlexanderJJBaoLJacobAKrausDMHolersVMQuiggRJ. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta2003; 1639: 169–176.
15.
AlexanderJJJacobAVezinaPSekineHGilkesonGSQuiggRJ. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol2007; 37: 1691–1701.
PierangeliSSVega-OstertagMLiuXGirardiG. Complement activation: A novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci2005; 1051: 413–420.
20.
ThurmanJMKrausDMGirardiG. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol2005; 42: 87–97.
21.
ZirkzeeEJSteup-BeekmanGMvan der MastRC. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol2012; 39: 2118–2126.
22.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
23.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
26.
WilsonWAGharaviAEKoikeT. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum1999; 42: 1309–1311.
27.
KatsumataYMiyakeKKawaguchiY. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: A controlled study of 126 consecutive patients. Arthritis Rheum2011; 63: 2436–2444.
28.
OrbaiAMTruedssonLSturfeltG. Anti-C1q antibodies in systemic lupus erythematosus. Lupus2015; 24: 42–49.
29.
SciasciaSBertolacciniMLRoccatelloDKhamashtaMASannaG. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: A systematic review. J Neurol2014; 261: 1706–1714.
30.
Zandman-GoddardGChapmanJShoenfeldY. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum2007; 36: 297–315.
31.
MehtaNUchinoKFakhranS. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke2008; 39: 3236–3241.
32.
NavratilJSManziSKaoAH. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum2006; 54: 670–674.
33.
OkuKAtsumiTBohgakiM. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis2009; 68: 1030–1035.
34.
DavisWDBreyRL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol1992; 10: 455–460.
35.
ZirkzeeEJMagro ChecaCSohrabianASteup-BeekmanGM. Cluster analysis of an array of autoantibodies in neuropsychiatric systemic lupus erythematosus. J Rheumatol2014; 41: 1720–1721.
36.
CeribelliAAndreoliLCavazzanaI. Complement cascade in systemic lupus erythematosus: Analyses of the three activation pathways. Ann N Y Acad Sci2009; 1173: 427–434.
37.
HorákPHermanováZZadrazilJ. C1q complement component and -antibodies reflect SLE activity and kidney involvement. Clin Rheumatol2006; 25: 532–536.
38.
MartoNBertolacciniMLCalabuigEHughesGRKhamashtaMA. Anti-C1q antibodies in nephritis: Correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis2005; 64: 444–448.
39.
MoroniGRadiceAGiammarresiG. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis2009; 68: 234–237.
40.
YinYWuXShanGZhangX. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: A meta-analysis. Lupus2012; 21: 1088–1097.
41.
TrouwLAGroeneveldTWSeelenMA. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest2004; 114: 679–688.
ChauSYMokCC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology2003; 61: 104–107.
44.
NishimuraKHarigaiMOmoriMSatoEHaraM. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology2008; 33: 395–403.
45.
NishimuraKOmoriMSatoE. New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: An observational case-series study. J Neurol2014; 261: 2150–2158.
46.
MayilyanKRWeinbergerDRSimRB. The complement system in schizophrenia. Drug News Perspect2008; 21: 200–210.
47.
WongCTTsoiWFSahaN. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res1996; 22: 165–171.
FrancksCTozziFFarmerA. Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13. Mol Psychiatry2010; 15: 319–325.
50.
NiJHuSZhangJTangWLuWZhangC. A preliminary genetic analysis of complement 3 gene and schizophrenia. PLoS One2015; 10: e0136372–e0136372.
51.
Pego-ReigosaJMIsenbergDA. Psychosis due to systemic lupus erythematosus: Characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford)2008; 47: 1498–1502.
52.
WatanabeTSatoTUchiumiTArakawaM. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: Diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus1996; 5: 178–183.
53.
HowellGRMacalinaoDGSousaGL. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest2011; 121: 1429–1444.
54.
RosenAMStevensB. The role of the classical complement cascade in synapse loss during development and glaucoma. Adv Exp Med Biol2010; 703: 75–93.
55.
StephanAHMadisonDVMateosJM. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci2013; 33: 13460–13474.
56.
SchaferDPLehrmanEKKautzmanAG. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron2012; 74: 691–705.
57.
SelkoeDJ. Alzheimer’s disease is a synaptic failure. Science2002; 298: 789–791.
58.
MichailidouIWillemsJGKooiEJ. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol2015; 77: 1007–1026.
59.
Magro ChecaCCohenDBollenELvan BuchemMAHuizingaTWSteup-BeekmanGM. Demyelinating disease in SLE: Is it multiple sclerosis or lupus?Best Pract Res Clin Rheumatol2013; 27: 405–424.
60.
SturfeltGSjöholmAG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol1984; 75: 75–83.
61.
MorganBPGasquePSinghraoSPiddlesdenSJ. The role of complement in disorders of the nervous system. Immunopharmacology1997; 38: 43–50.
62.
ThomasAGasquePVaudryDGonzalezBFontaineM. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol2000; 12: 1015–1023.
63.
DahaNABandaNKRoosA. Complement activation by (auto-) antibodies. Mol Immunol2011; 48: 1656–1665.
